Just caught that Merit Medical announced Martha Aronson as their new CEO starting October 2025, with Fred P. Lampropoulos stepping back to Chairman. Pretty interesting move - the guy founded the company back in 1987 and has been running it ever since, so this is a big deal for the organization.

What caught my eye though is the financial side. They're looking at Q2 2025 revenue between $380-384M, which is basically 12-14% growth year-over-year. Not bad for a medical device company. The preliminary numbers suggest solid momentum, though obviously these are unaudited estimates so there's always some uncertainty until the official filing.

Aronson's background is pretty solid too - spent time at Medtronic, Hill-Rom, Ecolab in various leadership roles. The board seems confident about the transition, and Fred P. Lampropoulos will stick around as Chairman to help with continuity. Insider trading data shows some executives have been selling shares recently, which is pretty normal during transition periods.

Analysts seem cautiously optimistic - Piper Sandler and Wells Fargo both have overweight ratings with price targets around $106-112. Not sure if this leadership change impacts the outlook much, but the revenue growth trajectory looks healthy heading into the transition. Worth keeping an eye on when they release full Q2 results.